105Ad7 cancer vaccine stimulates anti‐tumour helper and cytotoxic T‐cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses

No abstract is available for this paper.

• Publication year

  2000

• Venue

  International Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/(SICI)1097-0215(20000101)85:1<87::AID-IJC16>3.0.CO;2-KPMID 10585589
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity

  2004cited by this paper
• Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen

  1999cited by this paper
• Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen

  1999cited by this paper
• Decay accelerating factor (CD55): a target for cancer vaccines?

  1999cited by this paper
• A New Look at T Cells

  1998cited by this paper
• MHCPEP, a database of MHC-binding peptides: update 1997

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Idiotypic immunization induces immunity to mutated p53 and tumor rejection

  1998cited by this paper
• In vitro responses of human CD45R0brightRA− and CD45R0−RAbright T cell subsets and their relationship to memory and naive T cells

  1997cited by this paper
• MHCPEP, a database of MHC-binding peptides: update 1996

  1997cited by this paper
• Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7.

  1994cited by this paper
• Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains.

  1994cited by this paper
• Clinical outcome of colorectal cancer patients treated with human monoclonal anti‐idiotypic antibody

  1994cited by this paper
• Tolerance, danger, and the extended family.

  1994cited by this paper
• Contrasting efficacy of presentation by major histocompatibility complex class I and class II products when peptides are administered within a common protein carrier, self immunoglobulin

  1993cited by this paper
• Dependency on interleukin‐1 of primary human in vitro T cell responses to soluble antigens

  1992cited by this paper
• Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunization with human monoclonal anti-idiotypic antibody.

  1991cited by this paper
• Induction of delayed hypersensitivity to human tumor cells with a human monoclonal anti-idiotypic antibody.

  1991cited by this paper
• Interconversion of CD45R subsets of CD4 T cells in vivo

  1990cited by this paper
• Loss of CD45R and gain of UCHL1 reactivity is a feature of primed T cells.

  1988cited by this paper
• Operation manual for control of production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Prepared by a Joint Committee of the: Cancer Research Campaign National Institute for Biological Standards and Control.

  1986cited by this paper
• Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL1.

  1986cited by this paper
• Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IV. The suppressive effect of normal pregnancy.

  1978cited by this paper

• OTT_A_195182 4703..4712

  2019cites this paper
• Overexpression of CD55 correlates with tumor progression and poor prognosis in gastric stromal tumors

  2019cites this paper
• Therapeutic cancer vaccines.

  2017cites this paper
• Cancer vaccines

  2015cites this paper
• The potential role of immunotherapy to treat colorectal cancer

  2015cites this paper
• Fetal and Neonatal Illnesses Caused or Influenced by Maternal Transplacental IgG and/or Therapeutic Antibodies Applied During Pregnancy

  2012cites this paper
• Modulatory effects of tumor-derived heat shock protein in DNA vaccination against nasopharyngeal carcinoma.

  2011cites this paper
• Antibodies designed as effective cancer vaccines

  2009cites this paper
• Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

  2009cites this paper
• Natural human immunoglobulins in cancer immunotherapy.

  2009cites this paper
• Sensitization of Epithelial Cancer Cells with Human Monoclonal Antibodies

  2008cites this paper
• T-cell responses in osteosarcoma patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55.

  2008cites this paper
• Carcinoembryonic Antigen Transgenic Mouse Models for Immunotherapy and Development of Cancer Vaccines

  2008influential citation
• Development of cancer immunotherapeutics targeting complement regulatory protein CD55.

  2007cites this paper
• Generation of Her-2/neu vaccine utilizing idiotypic network cascade

  2007cites this paper
• Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu

  2007cites this paper
• Current immunotherapeutic strategies in colon cancer.

  2007cites this paper
• Peptidomimics of antigen are present in variable region of heavy and light chains of anti-idiotypic antibody and function as surrogate antigen for perpetuation of immunological memory.

  2007cites this paper
• Anti-Idiotype Antibody Vaccines for the Immunotherapy of Cancer

  2006cites this paper
• A Neoadjuvant/Adjuvant Randomized Trial of Colorectal Cancer Patients Vaccinated with an Anti-Idiotypic Antibody, 105AD7, Mimicking CD55

  2006cites this paper
• Anti‐idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen

  2006cites this paper
• Clinical results of vaccine therapy for cancer: learning from history for improving the future.

  2006cites this paper
• Immunologic therapies for gastrointestinal cancers.

  2005cites this paper
• Development of cancer vaccines to activate cytotoxic T lymphocytes

  2005cites this paper
• Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results.

  2005cites this paper
• Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

  2005cites this paper
• Development of a Delivery System for the Continuous Endogenous Release of an Anti-Idiotypic Antibody Against Ovarian Carcinoma

  2005cites this paper
• Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma

  2005cites this paper
• Using antibodies in tumour immunotherapy

  2004cites this paper
• Decay accelerating factor and colorectal cancer

  2004cites this paper
• Technology evaluation: Onyvax-105, Onyvax.

  2003cites this paper
• Cancer immunotherapy: an embarrassment of riches?

  2003cites this paper
• Active specific immunotherapy for colorectal cancer

  2003cites this paper
• Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines.

  2002cites this paper
• Current concepts in immunotherapy for the treatment of colorectal cancer.

  2002cites this paper
• Anti-idiotype antibody vaccine therapy for cancer

  2002influential citation
• An Anti-Idiotype Vaccine Elicits a Specific Response to N-Glycolyl Sialic Acid Residues of Glycoconjugates in Melanoma Patients1

  2002cites this paper
• of Glycoconjugates in Melanoma Patients -Glycolyl Sialic Acid Residues N Response to An Anti-Idiotype Vaccine Elicits a Specific

  2002cites this paper
• Colorectal Tumor Immunity

  2002cites this paper
• Anti-idiotype antibody vaccine therapies of cancer.

  2002cites this paper
• 13. Colorectal Tumor Immunity

  2002cites this paper
• Adoptive immunotherapy monitored by micro-MRI in experimental colorectal liver metastasis.

  2002cites this paper
• Regulation of the New Coexpressed CD55 (Decay-Accelerating Factor) Receptor on Stomach Carcinoma Cells Involved in Antibody SC-1–Induced Apoptosis

  2001cites this paper
• Human anti‐idiotypic antibodies can be good immunogens as they target FC receptors on antigen‐presenting cells allowing efficient stimulation of both helper and cytotoxic T‐cell responses

  2001cites this paper
• Are solid tumor anti-idiotype vaccines ready for prime time? Commentary re: U. Wagner et al., Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin. Cancer Res., 7: 1154-1162, 2001.

  2001cites this paper
• The anti-idiotype vaccines for immunotherapy.

  2001cites this paper
• Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

  2001cites this paper
• Review Current Concepts in Cancer Vaccine Strategies

  2001cites this paper
• CD55 is over-expressed in the tumour environment

  2001cites this paper
• [Tumor vaccination using monoclonal antibodies].

  2001cites this paper
• HUMA NANTI-IDIOTYPI CANTIBODIE SCA NB EGOO DIMMUNOGEN SAS THE YTARGE TF CRECEPTOR SO NANTIGEN-PRESENTIN GCELL SALLOWING EFFICIEN TSTIMULATIO NO FBOT HHELPE RAN DCYTOTOXI CT-CELL RESPONSES

  2001cites this paper
• Current concepts in cancer vaccine strategies.

  2001cites this paper
• Anti-idiotypic vaccination

  2001cites this paper
• A therapeutic human anti‐idiotypic antibody mimics CD55 in three distinct regions

  2000cites this paper
• A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55.

  2000cites this paper
• Cancer vaccines

  2000cites this paper